SLC5A2 and diabetes mellitus: Thereby, the use of this therapy has improved glycemic control, provided nephroprotection, and protected vascular endothelium in both clinical and experimental studies The present study demonstrated the protective efficacy of a selective SGLT2 inhibitor Dapa and a long-acting GLP-1 receptor agonist Lira and their combination therapy in DM-accompanied organ injury (24).